Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Cash from Operations (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Cash from Operations for 3 consecutive years, with 13254000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 44.66% to 13254000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 49143000.0 through Dec 2025, down 9.56% year-over-year, with the annual reading at 49143000.0 for FY2025, 9.56% down from the prior year.
  • Cash from Operations hit 13254000.0 in Q4 2025 for Compass Therapeutics, down from 10849000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 5922000.0 in Q3 2023 to a low of 13888000.0 in Q1 2024.
  • Historically, Cash from Operations has averaged 11218000.0 across 3 years, with a median of 11441500.0 in 2024.
  • Biggest YoY gain for Cash from Operations was 25.84% in 2024; the steepest drop was 86.61% in 2024.
  • Year by year, Cash from Operations stood at 12354000.0 in 2023, then grew by 25.84% to 9162000.0 in 2024, then crashed by 44.66% to 13254000.0 in 2025.
  • Business Quant data shows Cash from Operations for CMPX at 13254000.0 in Q4 2025, 10849000.0 in Q3 2025, and 11832000.0 in Q2 2025.